Lloyd N S, Douketis J D, Moinuddin I, Lim W, Crowther M A
Department of Medicine, McMaster University, and St Joseph's Healthcare, Hamilton, ON, Canada.
J Thromb Haemost. 2008 Mar;6(3):405-14. doi: 10.1111/j.1538-7836.2007.02847.x. Epub 2007 Nov 20.
The effect of anticoagulant prophylaxis on the prevention of deep vein thrombosis (DVT) should include an investigation of both clinical and subclinical DVT. We conducted a systematic review to determine whether anticoagulant prophylaxis reduces the risk of asymptomatic DVT compared to no prophylaxis in at-risk hospitalized medical patients.
MEDLINE, EMBASE, and the Cochrane Library were searched through March 2007 for randomized trials of anticoagulant prophylaxis for the prevention of asymptomatic DVT, assessed by venogram or ultrasound. We assessed four outcomes: all asymptomatic DVT, asymptomatic proximal DVT, major bleeding and mortality. Random effects meta-analyses were performed and results were expressed using relative risk (RR) and 95% confidence intervals (95% CIs).
Four trials including 5516 patients were eligible. Our pooled analysis demonstrated that compared to placebo, anticoagulant prophylaxis was associated with a significantly lower risk of any asymptomatic DVT (RR 0.51; 95% CI 0.39-0.67) and asymptomatic proximal DVT (RR 0.45; 95% CI 0.31-0.65). Anticoagulant prophylaxis was associated with a significantly increased risk of major bleeding compared to placebo (RR 2.00; 95% CI 1.05-3.79). There was no significant difference in the pooled estimate for all-cause mortality. Anticoagulant prophylaxis conferred an absolute risk reduction of any DVT and proximal DVT of 2.6% and 1.8%, respectively, and was associated with a 0.5% absolute risk increase in major bleeding.
Anticoagulant prophylaxis is effective in preventing asymptomatic DVT in at-risk hospitalized medical patients but is associated with an increased bleeding risk. The therapeutic benefits of anticoagulant prophylaxis appear to outweigh the risks of bleeding.
抗凝预防对预防深静脉血栓形成(DVT)的效果应包括对临床和亚临床DVT的调查。我们进行了一项系统评价,以确定与未进行预防相比,抗凝预防是否能降低有风险的住院内科患者无症状DVT的风险。
检索MEDLINE、EMBASE和Cochrane图书馆截至2007年3月的关于抗凝预防无症状DVT的随机试验,通过静脉造影或超声评估。我们评估了四个结局:所有无症状DVT、无症状近端DVT、大出血和死亡率。进行随机效应荟萃分析,并使用相对风险(RR)和95%置信区间(95%CI)表示结果。
四项试验共纳入5516例患者,符合纳入标准。我们的汇总分析表明,与安慰剂相比,抗凝预防可显著降低任何无症状DVT(RR 0.51;95%CI 0.39 - 0.67)和无症状近端DVT(RR 0.45;95%CI 0.31 - 0.65)的风险。与安慰剂相比,抗凝预防与大出血风险显著增加相关(RR 2.00;95%CI 1.05 - 3.79)。全因死亡率的汇总估计无显著差异。抗凝预防使任何DVT和近端DVT的绝对风险分别降低2.6%和1.8%,并与大出血的绝对风险增加0.5%相关。
抗凝预防对有风险的住院内科患者预防无症状DVT有效,但与出血风险增加相关。抗凝预防的治疗益处似乎超过出血风险。